Rosinha, ARabaça, CCalais, FPinto, JMBarreira, JVFernandes, RRamos, RFialho, ACPalma dos Reis, J2024-02-142024-02-142024Front Oncol . 2024 Jan 23:13:1266369.http://hdl.handle.net/10400.26/49844Non-metastatic castration-resistant prostate cancer (nmCRPC) represents a challenging disease state in prostate cancer care. nmCRPC patients with a high risk of progression to metastatic disease who are identified by a prostate-specific antigen doubling time (PSADT) ≤10 months are eligible for treatment with the novel androgen receptor inhibitors (ARIs), shown to delay disease progression and extend survival. However, nmCRPC is often unexploited in clinical practice due to a lack of standardization in the methodology and in the tools used for its identification. In this article, a group of Urology and Oncology specialists with acknowledged expertise in prostate cancer reviews the state of the art in the management of high-risk nmCRPC patients, identifies gaps and unmet needs, and proposes strategies to optimize the identification of this patient subgroup in the clinical practice and improve their health outcomes.engNeoplasias de Próstata Resistentes à CastraçãoProstatic Neoplasms, Castration-Resistantjournal article10.3389/fonc.2023.1266369